The Di Bella Method (DBM)

Introduction ^{(full pdf)}

The rationale, the aims, the components, the biochemical and physiological bases and the molecular biology mechanisms of action of the DBM are described. The tolerability, the clinical findings and the confirmation in the literature of the antitumoural efficacy of each individual component of the DBM, enhanced by the synergic factorial effect, are reported "The serious numerous irregularities that totally delegitimised the DBM experiments in 1998" (see below with complete transcription here) are also pointed out. The positive results achieved with the retrospective observational study on patients treated with the DBM are reported.

The current data in the literature on chemotherapy document a high degree of toxicity and a mortality percentage also reported by the Reuters Health Agency (Wesport, CT 2001-05-17): “Unexpected high mortality rates associated with chemotherapy regimen...”. This is confirmed by a study of the chemotherapy protocols for lymphoproliferative diseases (Atra et al. 1998) which reports a mortality rate of 11%, not caused by the tumour but solely by the chemotherapy.

The current survival of patients with tumours is mainly due to surgery, much less to radiotherapy, reaching 29% at 5 years (Richards et al. 2000). Of this 29%, only 2.1–2.5% is due to chemotherapy (Morgan et al. 2005). This fundamental publication is based on 14 years of observation, 225,000 patients and 22 types of tumour, aimed at ascertaining the true contribution of chemotherapy in achieving 5 years of survival (see "How effective is chemo therapy?").

Chemotherapy alone, without surgery, thus allows only 2.1–2.5% of patients to survive for 5 years, after which it has been ascertained that half of these patients who have survived for five years will die in the long-term as a result of their tumour (Lopez et al. 1998). Data from the recent conferences of the American Society of Clinical Oncology (ASCO) clearly show that in solid tumours monoclonal antibodies allow an average increase in survival of around two months, and only in rare cases, with or without associated chemotherapy, does this figure rise to or exceed four months.

Based on these data reported in the literature, we decided that it was appropriate to propose the new biological, physiological and rational therapy protocols of the DBM with greater efficacy and lower toxicity.

Read more: The Di Bella Method (DBM)